

08-11-2003

PATENT



HEET

RE

102520159
PATENT IS ONLY

8-7-03

TO: Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

Submission Type

- ☒ New
- ☐ Resubmission (Non-Recordation)

Document ID#: ☐ Correction of PTO ErrorReel #: Frame #: ☐ Corrective DocumentReel #: Frame #:

Conveyance Type

- ☒ Assignment ☐ Security Agreement
- ☐ License ☐ Change of Name
- ☐ Merger ☐ Other

U.S. Government

(For use ONLY by U.S. Government Agencies)

☐ Departmental File ☐ Secret File

Conveying Party(ies)

☐ Mark if additional names of conveying parties attachedName Bioventure Investments, kftExecution Date
Month Day Year

07/30/03

Name

/ /

Name

/ /

Name

/ /

Name

/ /

Receiving Party

☐ Mark if additional names of receiving parties attachedName (line 1) Investors Trust & Custodial Services (Ireland) Ltd., asName (line 2) Trustee on behalf of Royalty PharmaAddress (line 1) Block DAddress (line 2) Iveagh Court, Harcourt RoadAddress (line 3) Dublin 2 Ireland Zip Code

City

State/Country

☐ If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment)

Domestic Representative Name and Address

Enter for the first Receiving Party only.

Name Address (line 1) Address (line 2) Address (line 3) Address (line 4)

FOR OFFICE USE ONLY

08/08/2003 ECDUPER 00000108 9630198

01 FC:8021

240.00 DP

Mail documents to be recorded with required cover sheet(s) information to:

Mail Stop Assignment Recordation Services, Director of the US Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

PATENT

REEL: 014351 FRAME: 0162

Correspondent Name and Address

Area Code and Telephone Number (617) 248-7000

Name Patent Administrator

Address (line 1) Testa, Hurwitz & Thibault, LLP

Address (line 2) High Street Tower

Address (line 3) 125 High Street

Address (line 4) Boston, MA 02110

Pages Enter the total number of pages of the attached conveyance document including any attachments.

4

Application Number(s) or Patent Number(s)

☐ Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

Patent Application Number(s)

09/630,198

09/724,138

Patent Number(s)

5,500,362

5,677,180

5,721,108

6,120,767

Patent Cooperation Treaty (PCT)

Enter PCT application number
only if a U.S. Application Number
has not been assigned.

PCT

PCT

PCT

PCT

PCT

PCT

Number of Properties

Enter the total number of properties involved.

6

Fee Amount

Fee Amount for Properties Listed (37 CFR 3.41):

\$ 240.00

Method of Payment: Enclosed ☒Deposit Account ☐

Deposit Account

(Enter for payment by deposit account or if additional fees can be charged to the account)

Deposit Account Number # 20-0531

Authorization to charge additional fees: Yes ☒ No ☐

Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

Daniel A. Wilson, Reg. No. 45,508

Name of Person Signing



Signature

8/5/03

Date

ASSIGNMENT

WHEREAS, Bioventure Investments, kft, a company organized under the laws of Hungary and having a usual place of business at 1077 Budapest, Wesselényi u. 16., Budapest, Hungary and having company registration number Cg. 01-09-681100, hereinafter "ASSIGNOR", is owner and assignee of all interest in:

U.S. Pat. No. 5,500,362, issued March 19, 1996,
U.S. Pat. No. 5,677,180, issued October 14, 1997,
U.S. Pat. No. 5,721,108, issued February 24, 1998,
U.S. Pat. No. 6,120,767, issued September 19, 2000,
U.S. Appln. Ser. No. 09/630,198, filed August 1, 2000, and
U.S. Appln. Ser. No. 09/724,138, filed November 28, 2000.

WHEREAS, Investors Trust & Custodial Services (Ireland) Ltd. (having an address of Block D, Iveagh Court, Harcourt Road, Dublin 2, Ireland), as Trustee on behalf of Royalty Pharma, hereinafter "ASSIGNEE", desires to acquire an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR has sold, assigned and transferred and by these presents does hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR's entire right, title and interest in and throughout the United States, in and to the said inventions as described in said patents and patent applications, together with ASSIGNOR's entire right, title and interest in and to said patents and patent applications, and such Letters Patent as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions of said patents and patent applications or such Letters Patent; said inventions, patents and patent applications and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf, and for its successors, assigns and legal representatives, to the full end of the term for which said patents and Letters Patent may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby conveys all of ASSIGNOR's rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any applications for such patents or Letters Patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment. ASSIGNOR hereby acknowledges that this assignment, being of ASSIGNOR's entire right, title and interest in and to said inventions, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all Letters Patent to ASSIGNEE for its own name as assignee of ASSIGNOR's entire right, title and interest therein.


AND, ASSIGNOR hereby further agrees for itself and its successors, assigns and legal representatives to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid inventions to said ASSIGNEE, its successors, assigns, and legal representatives, but at its expense and charges, including: the execution of applications for patents in foreign countries; the execution of substitution, reissue, reexamination, divisional or continuation applications; and preliminary or other statements or the giving of testimony in any interference or other proceeding in which said inventions or any application or patent directed thereto may be involved.

AND, ASSIGNOR hereby authorizes and requests the Director of the United States Patent and Trademark Office to issue such Letters Patent as shall be granted upon said patent applications or other patent applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be duly executed and set our hands and affixed our seals the date set forth below.

BIOVENTURE INVESTMENTS, KFT

By: 

Name: Dave Madden

Title: Attorney-in-fact

Witnessed by: 

Name: Alexander B. Kuit

Date: 30 July 2003

**Investors Trust & Custodial Services (Ireland) Ltd.
Trustee for Royalty Pharma**

By: _____

Name: _____

Title: _____

Witnessed by: _____

Name: _____

Date: _____

IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be duly executed and set our hands and affixed our seals the date set forth below.

BIOVENTURE INVESTMENTS, KFT

By: _____

Name: _____

Title: _____

Witnessed by: _____

Name: _____

Date: _____

**Investors Trust & Custodial Services (Ireland) Ltd.
Trustee for Royalty Pharma**

By: William McManus

Name: William McManus

Title: Director

Witnessed by: Jacqui Horgan

Name: Jacqui Horgan

Date: 30 July 2003